Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients - 06/08/11
Résumé |
As breast cancer survival increases, cardiotoxicity associated with chemotherapeutic regimens such as anthracyclines and trastuzumab becomes a more significant issue. Assessment of the left ventricular (LV) ejection fraction fails to detect subtle alterations in LV function. The objective of this study was to evaluate whether more sensitive echocardiographic measurements and biomarkers could predict future cardiac dysfunction in chemotherapy-treated patients. Forty-three patients diagnosed with breast cancer who received anthracyclines and trastuzumab therapy underwent echocardiography and blood sampling at 3 time points (baseline and 3 and 6 months during the course of chemotherapy). The LV ejection fraction; peak systolic myocardial longitudinal, radial, and circumferential strain; echocardiographic markers of diastolic function; N-terminal pro–B-type natriuretic peptide; and high-sensitivity cardiac troponin I were measured. Nine patients (21%) developed cardiotoxicity (1 at 3 months and 8 at 6 months) as defined by the Cardiac Review and Evaluation Committee reviewing trastuzumab. A decrease in longitudinal strain from baseline to 3 months and detectable high-sensitivity cardiac troponin I at 3 months were independent predictors of the development of cardiotoxicity at 6 months. The LV ejection fraction, parameters of diastolic function, and N-terminal pro–B-type natriuretic peptide did not predict cardiotoxicity. In conclusion, cardiac troponin plasma concentrations and longitudinal strain predict the development of cardiotoxicity in patients treated with anthracyclines and trastuzumab. The 2 parameters may be useful to detect chemotherapy-treated patients who may benefit from alternative therapies, potentially decreasing the incidence of cardiotoxicity and its associated morbidity and mortality.
Le texte complet de cet article est disponible en PDF.Plan
Dr. Scherrer-Crosbie was supported by an investigator-initiated grant from the Susan G. Komen for the Cure Foundation, Dallas, Texas, a Claflin Distinguished Scholar Award, and a Clinical Innovation Award, Boston, Massachusetts. Dr. Ky was supported by the Kynett Focus Junior Faculty Investigator Award, Philadelphia, Pennsylvania. |
|
Dr. Januzzi has received grant support from Roche Diagnostics GmbH, Mannheim, Germany, Siemens Medical Systems, Erlangen, Germany, and Critical Diagnostics, San Diego, California. Dr. Plana is on the speaker's bureau of GE Healthcare, Milwaukee, Wisconsin. |
Vol 107 - N° 9
P. 1375-1380 - mai 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?